阅读说明：本技术 给药kras抑制剂治疗癌症 (Treatment of cancer by administration of KRAS inhibitors ) 是由 H·赫纳里 J·R·利普富德 V·J·西 于 2020-05-13 设计创作，主要内容包括：本文提供了向癌症受试者施用KRASG12C抑制剂,即AMG-510的方法。CA19-9和CEA生物标志物。(Provided herein are methods of administering a KRASG12C inhibitor, namely AMG-510, to a cancer subject. CA19-9 and CEA biomarkers.)

1. A method of treating cancer, comprising administering compound a to a subject in need thereof at a daily dose of 180mg, 360mg, 720mg, or 960mg, wherein compound a has the structure

2. The method of claim 1, wherein compound a has the structure

3. The method of claim 1, wherein compound a has the structure

4. The method of any one of claims 1,2, or 3, wherein the cancer is a solid tumor.

5. The method of any one of claims 1,2, 3, or 4, wherein the cancer is non-small cell lung cancer.

6. The method of any one of claims 1-4, wherein the cancer is colorectal cancer.

7. The method of any one of claims 1-4, wherein the cancer is pancreatic cancer.

8. The method of any one of claims 1 to 7, wherein the cancer is a KRAS G12C mutant cancer.

9. The method of any one of claims 1 to 8, wherein the subject has undergone at least one other systemic cancer therapy prior to initiating compound a therapy.

10. The method of claim 9, wherein the subject has undergone at least two other systemic cancer therapies.

11. The method of any one of claims 1-9, wherein compound a is administered orally.

12. The method of any one of claims 1-11, wherein the compound a is administered in a single daily dose.

13. The method of any one of claims 1 to 12, wherein the subject does not exhibit any grade 3 or grade 4 adverse events associated with compound a therapy after administration of compound a for at least 1 month.

14. The method of claim 13, wherein the subject does not exhibit any grade 3 or grade 4 adverse events associated with compound a therapy after administration of compound a for at least 3 months.

15. The method of any one of claims 1-14, wherein the dose of compound a is 180 mg.

16. The method of any one of claims 1-14, wherein the dose of compound a is 360 mg.

17. The method of any one of claims 1-14, wherein the dose of compound a is 720 mg.

18. The method of any one of claims 1-14, wherein the dose of compound a is 960 mg.

19. The method of any one of claims 1-18, wherein the subject is administered compound a for at least one month.

20. The method of any one of claims 1-18, wherein the subject is administered compound a for at least three months.

21. The method of any one of claims 1-18, wherein the subject is administered compound a for at least six months.

22. The method of any one of claims 19-21, wherein the subject exhibits at least a Stability Disease (SD).

23. The method of claim 22, wherein the subject exhibits at least a Partial Response (PR).

24. The method of any one of claims 1-23, wherein the subject does not exhibit dose-limiting toxicity (DLT).

25. The method of any one of claims 1-24, wherein compound a is the M atropisomer.

26. The method of any one of claims 1 to 25, further comprising administering a chemotherapeutic agent to the subject.

27. The method of claim 24, wherein the chemotherapeutic agent comprises an anti-PD 1 antibody.

28. The method of claim 25, wherein the anti-PD 1 antibody is pabulizumab (Keytruda), nivolumab, AUNP-12, AMG 404, or pidilizumab.

29. The method of claim 26, wherein the chemotherapeutic agent comprises an anti-PDL 1 antibody.

30. The method of claim 29, wherein the anti-PDL 1 antibody is atelizumab, MPDL3280A, avizumab, or dulvacizumab.

31. The method of claim 26, wherein the chemotherapeutic agent comprises a MEK inhibitor.

32. The method of claim 31, wherein the MEK inhibitor is trametinib, pimecrotinib, PD-325901, MEK162, TAK-733, GDC-0973, or AZD 8330.

33. The method of claim 26, wherein the chemotherapeutic agent comprises a CDK4/6 inhibitor.

34. The method of claim 33, wherein the CDK4/6 inhibitor comprises abelian or patienipride.

35. The method of claim 26, wherein the chemotherapeutic agent comprises a PI3K inhibitor.

36. The method of claim 35, wherein the PI3K inhibitor comprises AMG 511 or buparhenicy.

37. The method of claim 22, wherein the stable disease is neither sufficiently reduced to comply with PR nor sufficiently increased to comply with PD.

38. The method of claim 23, wherein the partial response is at least a 30% reduction in the sum of target lesion diameters.

Background

KRAS gene mutations are commonly seen in pancreatic, lung adenocarcinoma, colorectal, gall bladder, thyroid, and bile duct cancers. KRAS mutations are also observed in about 25% of NSCLC patients, and some studies have indicated that KRAS mutations are negative prognostic factors in NSCLC patients. Recently, it has been found that V-Ki-ras2 Kirsten rat sarcoma virus oncogene homolog (KRAS) mutation results in resistance to Epidermal Growth Factor Receptor (EGFR) targeted therapies in colorectal cancer; thus, the mutational status of KRAS may provide important information prior to the development of TKI therapy. In general, there is a need for new medical treatments for pancreatic, lung adenocarcinoma or colorectal cancer patients, especially patients that have been diagnosed with such cancers characterized by KRAS mutations and patients that include disease progression following chemotherapy. Oncogenic KRAS mutations at residues G12, G13 and Q61 represent the most common RAS mutations found in solid malignancies. It has recently been demonstrated that KRAS^G12CCan be targeted by a covalent small molecule inhibitor that reacts with a mutant cysteine adjacent to a switch II pocket (SIIP) to lock KRAS in its inactive GDP-binding state.

KRAS is the most frequently mutated oncogene in human cancers, encoding a key signal transduction protein in tumors. KRAS^G12CMutants carry cysteines which have been used to design covalent inhibitors with promising preclinical activity. We have optimized a series of inhibitors with novel binding interactionsAnd significantly enhanced potency and selectivity. These efforts led to the discovery of AMG 510 (also referred to herein as compound a), the first KRAS in clinical development for AMG 510^G12CAnd (3) an inhibitor. Preclinical AMG 510 treatment can regress KRAS p.g12c tumors and significantly improve the anti-tumor efficacy of chemotherapy and targeted agents. In immunocompetent (immune-competent) mice, AMG 510 treatment creates a pro-inflammatory tumor microenvironment, and in combination with immune checkpoint inhibition creates a durable treatment. Cured mice reject isogenic KRAS p.g12d tumor growth, suggesting adaptive immunity to shared antigens. AMG 510 demonstrated preliminary evidence of clinical anti-tumor activity in the first dose cohort, representing a potential revolutionary therapy for patients lacking effective treatment.

KRAS oncoprotein is a gtpase, an important mediator of intracellular signal transduction pathways involved in tumor cell growth and survival. In normal cells, KRAS acts as a molecular switch, switching between an inactive GDP-bound state and an active GTP-bound state. Conversion between these states is facilitated by guanine nucleotide exchange factor (GEF) loading GTP and activating KRAS, and GTP hydrolysis, catalyzed by Gtpase Activating Protein (GAP) to inactivate KRAS. GTP binding to KRAS promotes effector binding to trigger signal transduction pathways, including the RAF-MEK-erk (mapk) pathway. Activating mutations in KRAS in somatic cells are hallmarks of cancer and prevent GAP association, thereby stabilizing effector binding and enhancing KRAS signaling. Patients with KRAS mutant tumors had significantly worse outcomes and worse prognosis. Although several inhibitors of MAPK pathway proteins (e.g. MEK, BRAF, EGFR) have been clinically approved for use in some tumor types, to date there are no clinical molecules that are selective for KRAS mutant tumors. Moreover, due to lack of clinical efficacy, several MAPK pathway-targeted therapies were banned for the treatment of KRAS mutant tumors. Furthermore, non-tumor or non-mutated selective therapies may introduce on-target toxicity due to inhibition of MAPK signaling in normal cells. This may limit the utility of such agents for use in combination with standard of care or immunotherapy. Therefore, there is a clear unmet need to develop tumor-selective therapies that do not introduce a burden on normal cells.

G12c is present in about 13% lung adenocarcinoma, 3% colorectal cancer and 2% other solid tumors. KRAS^G12CAdjacent to the pocket (P2) present in KRAS in the inactive GDP-bound form. The proximity of P2 and the mutant cysteine led to an extensive search for covalent inhibitors. First reported to KRAS^G12CFinally, ARS-1620 was identified, which showed in vivo efficacy in the preclinical KRAS p.g12c model. Although ARS-1620 of arrychos pharmaceuticals (Araxes Pharma) is a concept-validated milestone for mutation-selective KRAS inhibition, it was targeted as a tool compound for preclinical studies. We have identified a series of novel acrylamide-based molecules that utilize KRAS^G12CSurface grooves (surface grooves) that have not been utilized before, thereby substantially improving the efficacy and selectivity. Extensive electrophilic screening and structure-based design ultimately led to the discovery of AMG 510, the first KRAS tested clinically in humans for AMG 510^G12CInhibitors (see www.clinicaltrials.govNCT03600883). Herein we describe the convincing clinical activity of AMG 510.

Disclosure of Invention

Provided herein are methods of treating cancer, comprising administering to a subject in need thereof a daily dose of 180mg, 360mg, 720mg, or 960mg of compound a. In each case, the daily dose was 180 mg. In each case, the daily dose was 360 mg. In each case, the daily dose was 720 mg. In each case, the daily dose was 960 mg. The dose may be administered orally. The dose may be administered as a single daily dose. In each case, compound a is administered to the subject for at least one month, or at least three months, or at least six months.

The subject to which the compound is administered in the methods disclosed herein has cancer. The cancer may be a solid tumor. The cancer may be a KRAS G12C mutant cancer. In some cases, the cancer is non-small cell lung cancer. In some cases, the cancer is colorectal cancer. In some cases, the cancer is pancreatic cancer. In various instances, the subject is one who has undergone at least one (e.g., at least two) other systemic cancer therapies prior to initiating therapy with compound a.

In each case, subjects administered compound a for at least one month did not exhibit any grade 3 or grade 4 adverse events associated with compound a therapy. In certain instances, the subject does not exhibit any grade 3 or grade 4 adverse events associated with compound a therapy after at least three months of administration of compound a. In each case, the subject exhibited at least a stable disease after administration of compound a. In certain instances, the subject exhibits at least a partial response following administration of compound a.

In various instances, the methods disclosed herein can further comprise administration of a chemotherapeutic agent. In certain instances, the chemotherapeutic agent comprises an anti-PD 1 antibody. In certain instances, the anti-PD 1 antibody is pabulizumab (Keytruda), Nivolumab (Nivolumab), AUNP-12, AMG 404, or Pidilizumab (Pidilizumab). In certain instances, the chemotherapeutic agent comprises an anti-PDL 1 antibody. In certain instances, the anti-PDL 1 antibody is alelizumab (Atezolizumab), MPDL3280A, avilumab (Avelumab), or dolvuzumab (Durvalumab). In certain instances, the chemotherapeutic agent comprises a MEK inhibitor. In certain instances, the MEK inhibitor is trametinib, pimavartib, PD-325901, MEK162, TAK-733, GDC-0973, or AZD 8330. In some cases, the chemotherapeutic agent comprises a CDK4/6 inhibitor. In some cases, the CDK4/6 inhibitor comprises abelian or palbociclib. In certain instances, the chemotherapeutic agent comprises a PI3K inhibitor. In some cases, the PI3K inhibitor comprises AMG 511 or buparlisib (buparlisib).

Drawings

In the following figures, PD indicates progressive disease, PR partial response, and SD stable disease.

Figure 1 shows CA19-9 and CAE biomarker responses in patients with metastatic colon adenocarcinoma and administered compound a at a total daily dose of 360 mg.

Figure 2 shows non-small cell lung cancer (NSCLC) tumor responses of nine NSCLC cancer patients receiving various total daily doses of compound a as indicated, as measured by radiographic scans every six weeks.

Figure 3 shows the response and duration of treatment of NSCLC patients administered compound a at the following total daily dose: top four columns (bar)960 mg; the next six columns 720 mg; the next column 360 mg; and the bottom three columns 180 mg.

Figure 4 shows colorectal cancer (CRC) and other solid tumor responses in patients with CRC and other solid tumor cancers receiving compound a at different total daily doses as indicated, as measured by radiographic scans every six weeks.

Figure 5 shows the response and duration of treatment of patients with CRC and other solid tumors administered compound a at the following total daily dose: the top two columns 960 mg; the next five columns 720 mg; the next seven columns 360 mg; and the bottom three columns 180 mg.

Figure 6 shows the efficacy of compound a as a change in tumor burden compared to baseline in NSCLC patients. The superscript "a" on the rightmost bar indicates that the patient has a complete response to the target lesion. The superscript "b" indicates that 1 patient discontinued the study due to clinical PD before assessment 1, and there was no post-baseline tumor burden data available, and therefore not shown in the figure.

Figure 7 shows the efficacy of compound a in NSCLC patients with respect to the time of appearance of response and duration of treatment. Each bar in the graph (23 bars in total) represents a patient (N23) who received a specific total daily dose (bars 1-3(180mg), 4(360mg), 5-10(720mg) and 11-23(960mg) counted from the top of the graph. the superscript "a" of bar 9 indicates that the graph was plotted from data received from the participating site (correlation site) by the time the data was cut off.

Fig. 8 shows the probability of progression free survival for CRC patients.

Fig. 9 shows the overall survival probability for CRC patients.

Fig. 10 shows tumor burden compared to baseline changes for CRC patients.

Figure 11 shows the tumor burden as a function of time from baseline in CRC patients at all four doses of compound a (total daily dose 180mg, 360mg, 720mg and 960 mg).

Fig. 12 shows the tumor burden versus baseline for the CRC patient subset shown in fig. 11 over time. Specifically, figure 12 shows a patient administered 180mg of compound a per day.

Fig. 13 shows the tumor burden versus baseline for the CRC patient subset shown in fig. 11 over time. Specifically, figure 13 shows a patient administered 360mg of compound a per day.

Fig. 14 shows the tumor burden versus baseline for the CRC patient subset shown in fig. 11 over time. Specifically, figure 14 shows patients administered 720mg of compound a per day.

Fig. 15 shows the tumor burden versus baseline for the CRC patient subset shown in fig. 11 over time. Specifically, figure 15 shows a patient administered 960mg of compound a per day.

FIG. 16 shows the time of appearance of response and treatment over time for CRC patients administered Compound A (counts from the top of the graph: columns 1-4(720mg), columns 5-14(360mg), and columns 15-17(180 mg).

Figure 17 shows the time to appearance of response and treatment over time in CRC patients administered 960mg of compound a per day.

Figure 18 shows the efficacy of compound a as a change in tumor burden compared to baseline in patients with advanced solid tumors other than NSCLC and CRC. The superscript "a" on some bars indicates that the patient has an unidentified PR. The superscript "b" on the particular three bars labeled PR indicates that one patient with appendiceal cancer received a total daily dose of 720mg of compound a, and that the other two patients (endometrial and melanoma) received a total daily dose of 960mg of compound a per person.

Figure 19 shows the time of occurrence of response and treatment over time for patients with advanced solid tumors other than NSCLC and CRC.

Detailed Description

Provided herein are methods of treating cancer by administering compound a to a subject in need thereof. The structure of the compound A isIn some cases, compound a is referred to as AMG 510. Compound a may exist as a pharmaceutically acceptable isotopically-labeled form, in which one or more atoms are replaced by an atom having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes which can be incorporated into the compounds A include isotopes of hydrogen, carbon, nitrogen, oxygen and fluorine, for example respectively²H、³H、¹¹C、¹³C、¹⁴C、¹³N、¹⁵N、¹⁵O、¹⁷O、¹⁸O and¹⁸F. these radiolabeled compounds can be used to help determine or measure the effectiveness of compound a by characterizing, for example, the site or mode of action, or binding affinity to a pharmacologically important site of action. Certain isotopically-labeled forms of compound a, for example those incorporating a radioisotope, are useful in drug and/or substrate tissue distribution studies. Radioactive isotope tritium (i.e. for its easy incorporation and ready-to-use detection means)³H) And carbon-14 (i.e.¹⁴C) And is particularly useful for this purpose.

Via heavier isotopes, such as deuterium, i.e.²H substitution may provide certain therapeutic benefits due to higher metabolic stability, e.g., increased in vivo half-life or reduced dosage requirements, and is therefore preferred in some cases.

With positron-emitting isotopes, such as¹¹C、¹⁸F、¹⁵O and¹³n substitution can be used in Positron Emission Tomography (PET) studies to examine substrate receptor occupancy. Isotopically-labelled compounds of structure (I) can generally be prepared by conventional techniques known to those skilled in the art. Isotopically-labeled compounds as disclosed herein can generally be prepared by conventional techniques known to those skilled in the art.

Compound a may exist as stereoisomers (i.e., isomers differing only in the spatial arrangement of the atoms), including optical isomers and conformers (or conformers).Unless otherwise indicated, when referred to herein, compound a includes all stereoisomers as pure individual stereoisomeric preparations and enriched preparations of each, as well as racemic mixtures of such stereoisomers, as well as individual diastereomers and enantiomers which may be separated according to methods known to those skilled in the art. In some cases, compound a is provided as: 4- ((S) -4-acryloyl-2-methylpiperazin-1-yl) -6-fluoro-7- (2-fluoro-6-hydroxyphenyl) -1- (2-isopropyl-4-methylpyridin-3-yl) pyrido [2,3-d]Pyrimidin-2 (1H) -one:

compound a may exist as an atropisomer, which is a conformational stereoisomer that occurs when rotation about a single bond in a molecule is prevented or greatly slowed due to steric interaction with other parts of the molecule. Unless otherwise indicated, when referred to herein, compound a includes all atropisomers as pure individual atropisomer preparations, enriched preparations of each, or unspecified mixtures of each. If the rotational barrier around a single bond is high enough and interconversion between conformations is slow enough, separation and separation of isomeric species can be tolerated. The separation and isolation of isomeric species is suitably indicated by the well-known and well-accepted symbol "M" or "P". In some cases, compound a is provided as: 4- ((S) -4-acryloyl-2-methylpiperazin-1-yl) -6-fluoro-7- (2-fluoro-6-hydroxyphenyl) -1- (2-isopropyl-4-methylpyridin-3-yl) pyrido [2,3-d]Pyrimidin-2 (1H) -one and M-atropisomers:in some cases, compound a is provided as: 4- ((R) -4-acryloyl-2-methylpiperazin-1-yl) -6-fluoro-7- (2-fluoro-6-hydroxyphenyl) -1- (2-isopropyl-4-methylpyridin-3-yl) pyrido [2,3-d]Pyrimidin-2 (1H) -one and M-atropisomers:

in some cases, compound a is provided as: 4- ((S) -4-acryloyl-2-methylpiperazin-1-yl) -6-fluoro-7- (2-fluoro-6-hydroxyphenyl) -1- (2-isopropyl-4-methylpyridin-3-yl) pyrido [2,3-d]Pyrimidin-2 (1H) -one and P-atropisomers:in some cases, compound a is provided as: 4- ((R) -4-acryloyl-2-methylpiperazin-1-yl) -6-fluoro-7- (2-fluoro-6-hydroxyphenyl) -1- (2-isopropyl-4-methylpyridin-3-yl) pyrido [2,3-d]Pyrimidin-2 (1H) -one and P-atropisomers:in some cases, compound a is provided as a mixture of the above isomers.

Compound a may be prepared as previously reported, for example as disclosed in WO 2018/119183 generally or as disclosed in WO 2018/217651 specifically.

Compound a may be provided as a pharmaceutically acceptable salt thereof. Contemplated examples of pharmaceutically acceptable salts include base addition salts and acid addition salts. Pharmaceutically acceptable base addition salts can be formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Pharmaceutically acceptable salts of the compounds may also be prepared with pharmaceutically acceptable cations. Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkali metal cations, alkaline earth metal cations, ammonium cations and quaternary ammonium cations. Carbonates or bicarbonates are also possible. Examples of metals used as cations are sodium, potassium, magnesium, ammonium, calcium or ferric iron and the like. Examples of suitable amines include isopropylamine, trimethylamine, histidine, N' -dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine. Pharmaceutically acceptable acid addition salts include inorganic or organic acid salts. Examples of suitable acid salts include hydrochloride, formate, acetate, citrate, salicylate, nitrate, phosphate. Other suitable pharmaceutically acceptable salts are well known to those skilled in the art and include, for example, salts of formic, acetic, citric, oxalic, tartaric or mandelic acid, hydrochloric, hydrobromic, sulfuric or phosphoric acid; salts with organic carboxylic, sulfonic, thioacid or phosphonic acids or N-substituted sulfamic acids, for example acetic acid, trifluoroacetic acid (TFA), propionic acid, glycolic acid, succinic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, fumaric acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid, glucuronic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4-aminosalicylic acid, 2-phenoxybenzoic acid, 2-acetoxybenzoic acid, pamoic acid, nicotinic acid or isonicotinic acid; and salts with amino acids, for example the 20 alpha amino acids which are involved in protein synthesis in nature, such as glutamic acid or aspartic acid, and salts with phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, ethane 1, 2-disulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfonic acid, naphthalene 2-sulfonic acid, naphthalene 1, 5-disulfonic acid, 2-phosphoglyceric acid or 3-phosphoglyceric acid, glucose 6-phosphate, N-cyclohexylsulfamic acid (for the formation of cyclamate salts), or salts with other acidic organic compounds, such as ascorbic acid.

Compound a may be combined with pharmaceutically acceptable excipients to provide a pharmaceutical formulation (also interchangeably referred to as a composition). The excipient may be a diluent or carrier. Suitable pharmaceutical formulations may be determined by the skilled person depending on the route of administration and the desired dosage. See, for example, Remington's Pharmaceutical Sciences, 1435-. Formulations can affect the physical state, stability, rate of in vivo release, and rate of in vivo clearance of the administered agent. Depending on the route of administration, suitable dosages may be calculated according to body weight, body surface area or organ size. Further refinement of the calculations necessary to determine an appropriate therapeutic dose can be made by one of ordinary skill in the art in a routine manner without undue experimentation, particularly in light of the dosage information and determinations disclosed herein, as well as the pharmacokinetic data available from animal or human clinical trials. The phrases "pharmaceutically acceptable" or "pharmacologically acceptable" refer to molecular entities and compositions that do not produce adverse, allergic, or other untoward reactions when administered to an animal or human. As used herein, "pharmaceutically acceptable" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such excipients for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the therapeutic composition, it is contemplated that it will be used in the therapeutic compositions. Supplementary active ingredients may also be incorporated into the compositions. In exemplary embodiments, the formulation may comprise corn syrup solids, high oleic safflower oil, coconut oil, soybean oil, L-leucine, tricalcium phosphate, L-tyrosine, L-proline, L-lysine acetate, DATEM (emulsifier), L-glutamine, L-valine, dipotassium hydrogen phosphate, L-isoleucine, L-arginine, L-alanine, glycine, L-asparagine monohydrate, L-serine, potassium citrate, L-threonine, sodium citrate, magnesium chloride, L-histidine, L-methionine, ascorbic acid, calcium carbonate, L-glutamic acid, L-cystine dihydrochloride, L-tryptophan, L-aspartic acid, choline chloride, taurine, m-inositol, soy protein, and soy protein, and soy protein, and L-protein, soy protein, and L-protein, L, Ferrous sulfate, ascorbyl palmitate, zinc sulfate, L-carnitine, alpha-tocopheryl acetate, sodium chloride, nicotinamide, mixed tocopherols, calcium pantothenate, ketone sulfate, thiamine chloride hydrochloride, vitamin A palmitate, manganese sulfate, riboflavin, pyridoxine hydrochloride, folic acid, beta-carotene, potassium iodide, phylloquinone, biotin, sodium selenate, chromium chloride, sodium molybdate, vitamin D3, and cyanocobalamine.

Pharmaceutical compositions containing compound a may be manufactured in a conventional manner, e.g. by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes. The appropriate formulation depends on the chosen route of administration.

For oral administration, suitable compositions can be readily formulated by combining compound a with pharmaceutically acceptable excipients (e.g., carriers) well known in the art. Such excipients and carriers enable compound a to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated. Pharmaceutical formulations for oral use can be obtained by: to compound a solid excipients are added, the resulting mixture is optionally ground, and the mixture of granules is processed, after addition of suitable auxiliaries (if desired), to obtain tablets or dragee cores. Suitable excipients include, for example, fillers and cellulose preparations. If desired, a disintegrant may be added. Pharmaceutically acceptable ingredients for use in various types of formulations are well known and may be, for example, binders (e.g., natural or synthetic polymers), lubricants, surfactants, sweeteners and flavoring agents, coating materials, preservatives, dyes, thickeners, adjuvants, antimicrobial agents, antioxidants and carriers for the various types of formulations.

In oral administration of a therapeutically effective amount of compound a, the composition is typically in the form of a solid (e.g., a tablet, capsule, pill, powder, or lozenge) or a liquid formulation (e.g., an aqueous suspension, solution, elixir, or syrup). In one embodiment, a therapeutically effective amount of compound a (e.g., 960mg) is administered orally in the form of a tablet or multiple tablets (e.g., 8x 120mg tablets).

When administered in tablet form, the compositions may additionally contain functional solids and/or solid carriers, such as gelatin or adjuvants. Tablets, capsules and powders may contain from about 1% to about 95% compound a, and preferably from about 15% to about 90% compound a.

When applied as a liquid or suspension, a functional liquid and/or liquid carrier may be added, such as water, petroleum or oils of animal or vegetable origin. The liquid form of the composition may further contain a physiological saline solution, a sugar alcohol solution, dextrose or other sugar solution, or a glycol. When applied as a liquid or suspension, the compositions may contain from about 0.5% to about 90% by weight of compound a, and preferably from about 1% to about 50% by weight of compound a. In one embodiment contemplated, the liquid carrier is non-aqueous or substantially non-aqueous. For application in liquid form, the composition may be supplied as a fast dissolving solid formulation for dissolution or suspension immediately prior to application.

When a therapeutically effective amount of compound a is administered by intravenous, transdermal or subcutaneous injection, the composition is in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable solutions should be well considered for pH, isotonicity, stability, etc. and is within the skill of the art. Preferred compositions for intravenous, transdermal or subcutaneous injection will generally contain an isotonic vehicle in addition to compound a. Such compositions may be prepared for administration as a solution of the free base or pharmacologically acceptable salt in water in suitable admixture with a surfactant such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof, and in oils. Under ordinary conditions of storage and use, these formulations may optionally contain a preservative to prevent microbial growth.

Injectable compositions may include sterile aqueous solutions, suspensions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions, suspensions or dispersions. In all embodiments, the form must be sterile and must be fluid to the extent that ready syringability exists. It must be stable under the conditions of manufacture and storage and must be resistant to the contaminating action of microorganisms, such as bacteria and fungi, by optionally including preservatives. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. In some embodiments contemplated, the carrier is non-aqueous or substantially non-aqueous. Proper fluidity can be maintained, for example, by: by using a coating, such as lecithin; by maintaining the desired particle size of the compound in the dispersion embodiment; and by using a surfactant. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many embodiments, it will be preferred to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions are prepared by incorporating compound a in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, the dispersion is prepared by: the various sterilized active ingredients are incorporated in a sterile vehicle which contains the base dispersion medium and the other required ingredients from those enumerated above. In the embodiment of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze-drying technique which yield a powder of the active ingredient plus any additional ingredient desired from a previously sterile-filtered solution thereof.

Slow-release or sustained-release formulations may also be prepared to achieve controlled release of compound a in contact with body fluids in the gastrointestinal tract and to provide substantially constant and effective levels of active compound in the plasma. For example, release may be controlled by one or more of dissolution, diffusion, and ion exchange. In addition, slow release methods may facilitate absorption through saturable or restricted pathways in the gastrointestinal tract. For example, the compounds may be embedded for this purpose in a polymer matrix of a biodegradable polymer, a water-soluble polymer or a mixture of both and optionally a suitable surfactant. In this case, embedding may mean incorporating the microparticles in a polymer matrix. Controlled release formulations are also obtained by encapsulating dispersed microparticles or emulsified microdroplets via known dispersion or emulsion coating techniques.

For administration by inhalation, compound a is delivered in the form of an aerosol spray presentation from pressurized packs or nebulizers using a suitable propellant. In embodiments of pressurized aerosols, the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, for example, gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

Compound a may be formulated for parenteral administration by injection (e.g., by bolus injection or continuous infusion). Formulations for injection may be presented in unit dosage form (e.g., in ampoules or in multi-dose containers) with an added preservative. The composition may take the form of, for example: suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.

Pharmaceutical formulations for parenteral administration comprise an aqueous solution of compound a in water-soluble form. Additionally, the suspension may be prepared as a suitable oily injection suspension. Suitable lipophilic solvents or vehicles include fatty oils or synthetic fatty acid esters. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension. Optionally, the suspension may also contain suitable stabilizers or agents that increase the solubility of compound a and allow for the preparation of highly concentrated solutions. Alternatively, the compositions of the present invention may be in powder form for constitution with a suitable vehicle (e.g., sterile, pyrogen-free water) before use.

Compound a may also be formulated in rectal compositions such as suppositories or retention enemas (e.g., containing conventional suppository bases). Compound a can be formulated as a depot formulation in addition to the formulations previously described. Such long-acting formulations may be administered by implantation (e.g., subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, compound a may be formulated with suitable polymeric or hydrophobic materials (e.g., as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives (e.g., as a sparingly soluble salt).

In particular, compound a can be administered orally, buccally or sublingually in the form of tablets containing excipients (e.g., starch or lactose), or in capsules or beadlets (ovule), either alone or in admixture with excipients, or in the form of elixirs or suspensions containing flavoring or coloring agents. Such liquid formulations may be prepared with pharmaceutically acceptable additives such as suspending agents. Compound a may also be injected parenterally, for example intravenously, intramuscularly, subcutaneously or intracoronary. For parenteral administration, the compounds are optimally used in the form of sterile aqueous solutions which may contain other substances, for example salts or sugar alcohols (e.g. mannitol) or glucose, to make the solution isotonic with blood.

For veterinary use, compound a is administered according to conventional veterinary practice as a suitably acceptable formulation. Veterinarians can readily determine the most appropriate dosing regimen and route of administration for a particular animal.

In some embodiments, all of the required components for treating a KRAS-related disorder using compound a (alone or in combination with another agent or intervention traditionally used to treat KRAS-related disorders) may be packaged into a kit. In particular, the present disclosure provides a kit for therapeutic intervention in a disease, the kit comprising a packaged kit comprising compound a together with buffers and other components for preparing a deliverable form of the medicament; and/or a device for delivering such a drug; and/or any agent used in combination therapy with compound a; and/or disease treatment instructions packaged with the medicament. The instructions may be fixed in any tangible medium, such as printed paper, or a computer readable magnetic or optical medium, or the instructions may be referenced from a remote computer data source, such as the world wide web accessible via the internet.

By "therapeutically effective amount" is meant an amount effective to treat or prevent the development of, or alleviate, an existing symptom in the subject being treated. Determination of an effective amount is well within the ability of those skilled in the art, particularly in light of the detailed disclosure provided herein. Generally, a "therapeutically effective dose" refers to the amount of compound a that results in the desired effect being achieved. For example, a therapeutically effective amount of compound a reduces KRAS activity by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, or at least 90% as compared to a control.

By "therapeutically effective amount" is meant an amount effective to treat or prevent the development of, or alleviate, an existing symptom in the subject being treated. Determination of an effective amount is well within the ability of those skilled in the art, particularly in light of the detailed disclosure provided herein. Generally, a "therapeutically effective dose" refers to an amount of a compound that results in the achievement of a desired effect. For example, in a preferred embodiment, a therapeutically effective amount of a compound disclosed herein reduces KRAS activity by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, or at least 90% as compared to a control.

Although individual requirements vary, determination of the optimal range for an effective amount of a compound is within the skill of the art. For administration to humans in the curative or prophylactic treatment of the conditions and disorders identified herein, for example, a typical dose of a compound of the disclosure may be from about 0.05 mg/kg/day to about 50 mg/kg/day, e.g., at least 0.05mg/kg, at least 0.08mg/kg, at least 0.1mg/kg, at least 0.2mg/kg, at least 0.3mg/kg, at least 0.4mg/kg, or at least 0.5mg/kg, and preferably 50mg/kg or less, 40mg/kg or less, 30mg/kg or less, 20mg/kg or less, or 10mg/kg or less, e.g., it may be from about 2.5 mg/day (0.5mg/kg x 5kg) to about 5000 mg/day (50mg/kg x 100 kg). For example, the dosage of the compound can be from about 0.1 mg/kg/day to about 50 mg/kg/day, from about 0.05 mg/kg/day to about 10 mg/kg/day, from about 0.05 mg/kg/day to about 5 mg/kg/day, from about 0.05 mg/kg/day to about 3 mg/kg/day, from about 0.07 mg/kg/day to about 3 mg/kg/day, from about 0.09 mg/kg/day to about 3 mg/kg/day, from about 0.05 mg/kg/day to about 0.1 mg/kg/day, from about 0.1 mg/kg/day to about 1 mg/kg/day, from about 1 mg/kg/day to about 10 mg/kg/day, from about 1 mg/kg/day to about 5 mg/kg/day, from about 1 mg/kg/day to about 3 mg/kg/day, or, About 1 mg/day to about 960 mg/day, about 20 mg/day to about 720 mg/day, about 3 mg/day to about 500 mg/day, about 5 mg/day to about 360 mg/day, about 10 mg/day to about 100 mg/day, about 3 mg/day to about 10 mg/day, about 100 mg/day to about 250 mg/day. Such doses may be administered as a single dose, or they may be divided into multiple doses.

In particular embodiments, compound a is administered orally to a subject in need thereof once a day. In some cases, the total daily amount administered to the subject is 180mg, 360mg, 720mg, or 960 mg. In some cases, the total daily amount of compound a administered is 180 mg. In some cases, the total daily amount of compound a administered is 360 mg. In some cases, the total daily amount of compound a administered is 720 mg. In some cases, the total daily amount of compound a administered is 960 mg. In certain instances, compound a is administered in divided daily doses, such as two, three, four, five, or six times per day.

Detailed description of the preferred embodiments

In a first embodiment, the present disclosure provides a method of treating cancer, the method comprising administering compound a to a subject in need thereof at a daily dose of 180mg, 360mg, 720mg, or 960mg, wherein compound a has the structure

In embodiment 2, the present disclosure provides the method of embodiment 1, wherein compound a has the structure

In embodiment 3, the present disclosure provides the method of embodiment 1, wherein compound a has the structure

In a 4 th embodiment, the present disclosure provides the method of any one of embodiments 1,2 or 3, wherein the cancer is a solid tumor.

In a 5 embodiment, the present disclosure provides the method of any one of embodiments 1,2, 3, or 4, wherein the cancer is non-small cell lung cancer.

In embodiment 6, the present disclosure provides the method of any one of embodiments 1-4, wherein the cancer is colorectal cancer.

In embodiment 7, the present disclosure provides the method of any one of embodiments 1-4, wherein the cancer is pancreatic cancer.

In an 8 th embodiment, the present disclosure provides the method of any one of embodiments 1 to 7, wherein the cancer is KRAS G12C mutant cancer.

In a 9 th embodiment, the present disclosure provides the method of any one of embodiments 1 to 8, wherein the subject has undergone at least one additional systemic cancer therapy prior to starting compound a therapy.

In a 10 th embodiment, the present disclosure provides the method of embodiment 9, wherein the subject has undergone at least two other systemic cancer therapies.

In an 11 embodiment, the present disclosure provides a method according to any one of embodiments 1 to 9, wherein compound a is administered orally.

In a 12 th embodiment, the present disclosure provides the method of any one of embodiments 1 to 11, wherein the compound a is administered in a single daily dose.

In a 13 th embodiment, the present disclosure provides the method of any one of embodiments 1 to 12, wherein the subject does not exhibit any grade 3 or grade 4 adverse events associated with compound a therapy after administration of compound a for at least 1 month.

In a 14 th embodiment, the present disclosure provides the method of embodiment 13, wherein the subject does not exhibit any grade 3 or grade 4 adverse events associated with compound a therapy after administration of compound a for at least 3 months.

In a 15 embodiment, the present disclosure provides a method according to any one of embodiments 1 to 14, wherein the dose of compound a is 180 mg.

In embodiment 16, the present disclosure provides a method according to any one of embodiments 1 to 14, wherein the dose of compound a is 360 mg.

In a 17 th embodiment, the present disclosure provides a method according to any one of embodiments 1 to 14, wherein the dose of compound a is 720 mg.

In an 18 th embodiment, the present disclosure provides the method of any one of embodiments 1-14, wherein the dose of compound a is 960 mg.

In a19 embodiment, the present disclosure provides a method according to any one of embodiments 1 to 18, wherein the subject is administered compound a for at least one month.

In a 20 th embodiment, the present disclosure provides the method of any one of embodiments 1 to 18, wherein the subject is administered compound a for at least three months.

In a 21 embodiment, the present disclosure provides a method according to any one of embodiments 1 to 18, wherein the subject is administered compound a for at least six months.

In an embodiment 22, the present disclosure provides the method of any one of embodiments 19 to 21, wherein the subject exhibits at least a Stability Disease (SD).

In an embodiment 23, the present disclosure provides the method of embodiment 22, wherein the subject exhibits at least a Partial Response (PR).

In an embodiment 24, the present disclosure provides the method of any one of embodiments 1 to 23, wherein the subject does not exhibit dose-limiting toxicity (DLT).

In an embodiment 25, the present disclosure provides the method of any one of embodiments 1 to 24, wherein compound a is M atropisomer (M atropisomer).

In a 26 embodiment, the present disclosure provides the method of any one of embodiments 1 to 25, further comprising administering to the subject a chemotherapeutic agent.

In embodiment 27, the present disclosure provides the method of embodiment 24, wherein the chemotherapeutic agent comprises an anti-PD 1 antibody.

In an embodiment 28, the present disclosure provides the method of embodiment 25, wherein the anti-PD 1 antibody is pabulizumab (Keytruda), nivolumab, AUNP-12, AMG 404, or pidilizumab.

In an 29 th embodiment, the present disclosure provides the method of embodiment 26, wherein the chemotherapeutic agent comprises an anti-PDL 1 antibody.

In a 30 embodiment, the present disclosure provides the method of embodiment 29, wherein the anti-PDL 1 antibody is atelizumab, MPDL3280A, avizumab, or dovuzumab.

In embodiment 31, the present disclosure provides the method of embodiment 26, wherein the chemotherapeutic agent comprises a MEK inhibitor.

In a 32 th embodiment, the present disclosure provides the method of embodiment 31, wherein the MEK inhibitor is trametinib, pimecretin, PD-325901, MEK162, TAK-733, GDC-0973, or AZD 8330.

In embodiment 33, the present disclosure provides the method of embodiment 26, wherein the chemotherapeutic agent comprises a CDK4/6 inhibitor.

In embodiment 34, the present disclosure provides the method of embodiment 33, wherein the CDK4/6 inhibitor comprises abelian or papaecari.

In embodiment 35, the present disclosure provides the method of embodiment 26, wherein the chemotherapeutic agent comprises a PI3K inhibitor.

In an embodiment 36, the present disclosure provides the method of embodiment 35, wherein the PI3K inhibitor comprises AMG 511 or buparhenib.

In an 37 th embodiment, the present disclosure provides the method of embodiment 22, wherein the stable disease is neither sufficiently reduced to comply with PR, nor sufficiently increased to comply with PD.

In embodiment 38, the present disclosure provides the method of embodiment 23, wherein the partial response is at least a 30% reduction in the sum of the target lesion diameters.

In an alternative first embodiment, the present disclosure provides a daily dose of 180mg, 360mg, 720mg, or 960mg of compound a for use in treating cancer, wherein compound a has the structure

In another alternative first embodiment, the present disclosure provides a use of a daily dose of 180mg, 360mg, 720mg, or 960mg of compound a in the manufacture of a medicament for treating cancer, wherein compound a has the structure

Methods of use of Compound A

In embodiments of the methods disclosed herein, compound a is administered to the subject at a disclosed dose for at least one month, at least six weeks, at least two months, at least three months, at least four months, at least five months, or at least six months.

In some embodiments of the methods disclosed herein, compound a is orally administered to the subject at a disclosed dose at least once daily (QD).

In some embodiments of the methods disclosed herein, compound a is administered orally to a subject at a disclosed dose at least twice daily (BID).

The present disclosure provides methods of inhibiting RAS-mediated cell signaling comprising contacting a cell with an effective amount of compound a. Inhibition of RAS-mediated signal transduction can be assessed and demonstrated by a variety of methods known in the art. Non-limiting examples include those that show (a) a decrease in the gtpase activity of RAS; (b) a decrease in GTP binding affinity or an increase in GDP binding affinity; (c) k of GTP_offK of increased or GDP_offReduction; (d) a reduction in the level of a downstream signaling molecule in the RAS pathway, e.g., a reduction in the levels of pMEK, pERK, or pAKT; and/or (e) reduced binding of the RAS complex to downstream signaling molecules including, but not limited to Raf. One or more of the above items can be determined using kits and commercially available assays.

The present disclosure also provides methods of using compound a or pharmaceutical compositions of the present disclosure to treat disease conditions, including but not limited to conditions (e.g., cancer) that are affected by mutations in G12C KRAS, HRAS, or NRAS.

In some embodiments, there is provided a method of treating cancer, comprising administering to a subject in need thereof an effective amount of compound a as disclosed herein. In some embodiments, the cancer is mediated by a KRAS, HRAS, or NRAS G12C mutation. In various embodiments, the cancer is pancreatic cancer, colorectal cancer, or lung cancer (e.g., non-small cell lung cancer (locally advanced or metastatic)). In some embodiments, the cancer is gallbladder cancer, thyroid cancer, and bile duct cancer.

In some embodiments, the present disclosure provides a method of treating a disorder in a subject in need thereof, wherein the method comprises determining whether the subject has a KRAS, HRAS or NRAS G12C mutation, and administering to the subject a therapeutically effective dose of compound a or a pharmaceutically acceptable salt thereof if the subject is determined to have a KRAS, HRAS or NRAS G12C mutation.

The disclosed compounds inhibit anchorage-independent cell growth and, therefore, have the potential to inhibit tumor metastasis. Accordingly, another embodiment of the present disclosure provides a method of inhibiting tumor metastasis, comprising administering an effective amount of compound a.

KRAS, HRAS or NRAS G12C mutations have also been identified in hematological malignancies (e.g., cancers affecting the blood, bone marrow and/or lymph nodes). Accordingly, certain embodiments relate to administering compound a (e.g., in the form of a pharmaceutical composition) to a patient in need of treatment for a hematologic malignancy. Such malignancies include, but are not limited to, leukemia and lymphoma. For example, compound a may be used to treat, for example, the following diseases: acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Chronic Myeloid Leukemia (CML), acute monocytic leukemia (AMoL), and/or other leukemias. In other embodiments, compound a may be used to treat lymphoma, such as all subtypes of hodgkin's lymphoma or non-hodgkin's lymphoma. In various embodiments, compound a can be used to treat plasma cell malignancies, such as multiple myeloma, mantle cell lymphoma, and fahrenheit macroglobulinemia.

Determining whether a tumor or cancer comprises a G12C KRAS, HRAS or NRAS mutation may be performed by assessing the nucleotide sequence encoding the KRAS, HRAS or NRAS protein, by assessing the amino acid sequence of the KRAS, HRAS or NRAS protein, or by assessing a putative characteristic of the KRAS, HRAS or NRAS mutant protein. The sequence of wild-type human KRAS, HRAS or NRAS is known in the art (e.g. accession No. NP 203524).

Methods for detecting mutations in KRAS, HRAS or NRAS nucleotide sequences are known to those skilled in the art. These methods include, but are not limited to, polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assays, polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) assays, real-time PCR assays, PCR sequencing, mutant allele specific PCR amplification (MASA) assays, direct sequencing, primer extension reactions, electrophoresis, oligonucleotide ligation assays, hybridization assays, TaqMan assays, SNP genotyping assays, high resolution melting assays, and microarray analysis. In some embodiments, the sample is assessed for the G12C KRAS, HRAS, or NRAS mutation by real-time PCR. In real-time PCR, fluorescent probes specific for KRAS, HRAS or NRAS G12C mutations were used. In the presence of the mutation, the probe binds and fluorescence is detected. In some embodiments, direct sequencing methods of specific regions (e.g., exon 2 and/or exon 3) in the KRAS, HRAS or NRAS genes are used to identify KRAS, HRAS or NRAS G12C mutations. This technique will identify all possible mutations in the sequenced region.

Methods for detecting mutations in KRAS, HRAS or NRAS proteins are known to those skilled in the art. These methods include, but are not limited to, detection of KRAS, HRAS or NRAS mutants using binding agents (e.g., antibodies) specific for the mutant proteins, protein electrophoresis and western blotting, and direct peptide sequencing.

Methods for determining whether a tumor or cancer comprises a G12C KRAS, HRAS, or NRAS mutation may use a variety of samples. In some embodiments, the sample is taken from a subject having a tumor or cancer. In some embodiments, the sample is a fresh tumor/cancer sample. In some embodiments, the sample is a frozen tumor/cancer sample. In some embodiments, the sample is a formalin fixed paraffin embedded sample. In some embodiments, the sample is a Circulating Tumor Cell (CTC) sample. In some embodiments, the sample is processed into a cell lysate. In some embodiments, the sample is processed into DNA or RNA.

The present disclosure also relates to methods of treating hyperproliferative disorders in a mammal comprising administering to said mammal a therapeutically effective amount of compound a or a pharmaceutically acceptable salt thereof. In some embodiments, the methods involve treating a subject having a cancer, e.g., acute myeloid leukemia, juvenile cancer, childhood adrenocortical carcinoma, AIDS-related cancers (e.g., lymphoma and kaposi's sarcoma), anal cancer, appendiceal cancer, astrocytoma, atypical teratomas, basal cell carcinoma, cholangiocarcinoma, bladder cancer, bone cancer, brain stem cell glioma, brain tumor, breast cancer, bronchial tumor, burkitt's lymphoma, carcinoid tumor, atypical teratoma, embryoma, germ cell tumor, primary lymphoma, cervical cancer, childhood cancer, chordoma, cardiac tumor, Chronic Lymphocytic Leukemia (CLL), Chronic Myelogenous Leukemia (CML), chronic myeloproliferative disorder, colon cancer, colorectal cancer, craniopharyngioma, cutaneous T-cell lymphoma, extrahepatic Ductal Carcinoma In Situ (DCIS), Embryonal carcinoma, CNS cancer, endometrial carcinoma, ependymoma, esophageal cancer, nasal glioma, ewing's sarcoma, extracranial germ cell tumor, extragonal germ cell tumor, ocular cancer, osteocyte cell tumor, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), germ cell tumor, gestational trophoblastic tumor, hairy cell leukemia, head and neck cancer, cardiac cancer, liver cancer, hodgkin's lymphoma, hypopharynx cancer, intraocular melanoma, islet cell tumor, pancreatic neuroendocrine tumor, kidney cancer, laryngeal cancer, lip and oral cancer (oral cavity cancer), liver cancer, Lobular Carcinoma In Situ (LCIS), lung cancer, lymphoma, metastatic squamous neck cancer with occult primary focus, midline cancer, oral cancer (mouth cancer), multiple endocrine syndrome, multiple myeloma/plasma cell tumor, mycosis fungoides, myelodysplastic syndrome, multiple myeloma-and plasmacytic syndrome, Myelodysplastic/myeloproliferative neoplasms, multiple myeloma, merkel cell carcinoma, malignant mesothelioma, malignant fibrous histiocytoma of bone and osteosarcoma, cancer of the nasal and paranasal sinuses, nasopharyngeal carcinoma, neuroblastoma, non-hodgkin's lymphoma, non-small cell lung cancer (NSCLC), oral cancer (oral cancer), cancer of the lips and oral cavity, oropharyngeal cancer, ovarian cancer, pancreatic cancer, papillomatosis, paragangliomas, paranasal sinuses and nasal cavity, parathyroid cancer, penile cancer, pharyngeal cancer, pleuropulmonoblastoma, primary Central Nervous System (CNS) lymphoma, prostate cancer, rectal cancer, transitional cell cancer, retinoblastoma, rhabdomyosarcoma, salivary gland carcinoma, skin cancer, gastric (stomach/gaic str) cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, T-cell lymphoma, testicular cancer, laryngeal cancer, neoplasms and carcinomas, thyroid cancer, cervical, Thyroid cancer, transitional cell carcinoma of the renal pelvis and ureter, trophoblastoma, rare cancer in children, cancer of the urethra, sarcoma of the uterus, vaginal cancer, vulvar cancer or virus-induced cancer. In some embodiments, the methods relate to treating a non-cancerous hyperproliferative disorder, such as benign hyperplasia of the skin (e.g., psoriasis), restenosis, or prostate (e.g., Benign Prostatic Hypertrophy (BPH)).

In some embodiments, the methods of treatment involve treating lung cancer, comprising administering to a subject in need thereof an effective amount of compound a (or a pharmaceutical composition comprising the compound). In certain embodiments, the lung cancer is non-small cell lung cancer (NSCLC), such as adenocarcinoma, squamous cell lung cancer, or large cell lung cancer. In some embodiments, the lung cancer is small cell lung cancer. Other lung cancers that may be treated with the disclosed compounds include, but are not limited to, adenomas, carcinoids and undifferentiated carcinomas.

The present disclosure further provides methods of modulating the activity of a G12C mutant KRAS, HRAS or NRAS protein by contacting the protein with an effective amount of compound a. Modulation may be inhibition or activation of protein activity. In some embodiments, the present disclosure provides methods of inhibiting protein activity by contacting a G12C mutant KRAS, HRAS or NRAS protein with an effective amount of compound a in solution. In some embodiments, the present disclosure provides methods of inhibiting the activity of a G12C mutant KRAS, HRAS or NRAS protein by contacting a cell, tissue or organ that expresses a protein of interest. In some embodiments, the present disclosure provides methods of inhibiting protein activity in a subject, including but not limited to rodents and mammals (e.g., humans), by administering to the subject an effective amount of compound a. In some embodiments, the percent adjustment is greater than 25%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%. In some embodiments, the percentage of inhibition is greater than 25%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%.

In some embodiments, the present disclosure provides methods of inhibiting KRAS, HRAS or NRAS G12C activity in a cell by contacting the cell with an amount of compound a sufficient to inhibit the activity of KRAS, HRAS or NRAS G12C in the cell. In some embodiments, the present disclosure provides methods of inhibiting KRAS, HRAS or NRAS G12C activity in a tissue by contacting the tissue with an amount of compound a sufficient to inhibit KRAS, HRAS or NRAS G12C activity in the tissue. In some embodiments, the present disclosure provides methods of inhibiting KRAS, HRAS or NRAS G12C activity in an organism by contacting the organism with an amount of compound a sufficient to inhibit the activity of KRAS, HRAS or NRAS G12C in the organism. In some embodiments, the present disclosure provides methods of inhibiting KRAS, HRAS or NRAS G12C activity in an animal by contacting the animal with an amount of compound a sufficient to inhibit the activity of KRAS, HRAS or NRAS G12C in the animal. In some embodiments, the present disclosure provides methods of inhibiting KRAS, HRAS or NRAS G12C activity in a mammal by contacting the mammal with an amount of compound a sufficient to inhibit KRAS, HRAS or NRAS G12C activity in the mammal. In some embodiments, the present disclosure provides methods of inhibiting KRAS, HRAS or NRAS G12C activity in a human by contacting the human with an amount of compound a sufficient to inhibit the activity of KRAS, HRAS or NRAS G12C in the human. The present disclosure provides methods of treating a disease mediated by KRAS, HRAS or NRAS G12C activity in a subject in need of such treatment.

Subject selection and treatment outcomes

In some embodiments, the subject treated with compound a in the disclosed methods is a subject that has undergone at least one or more prior systemic cancer therapies (e.g., compound a is a second-or third-line therapy). In some embodiments, the subject treated with compound a in the disclosed methods is a subject with disease progression after at least one prior systemic cancer therapy (i.e., compound a is a second line therapy). In some embodiments, the subject treated with compound a in the disclosed methods is a subject with disease progression after at least two prior systemic cancer therapies (i.e., compound a is a three-line therapy). The prior systemic cancer therapy may be any therapy approved by regulatory agencies (e.g., FDA or EMA) for the treatment of a given cancer type and stage. In certain instances, the prior systemic cancer therapy is a cancer therapy that is not approved by a regulatory agency, but is undergoing clinical trials. If the subject has undergone a prior systemic cancer therapy, in certain instances, the subject has not undergone any systemic cancer therapy for at least one month, at least two months, at least three months, at least four months, at least five months, or at least six months prior to initiating the therapy with compound a disclosed herein.

In some embodiments, the subject will exhibit a pathologically-demonstrated locally advanced or metastatic malignancy having a krasp.g12c mutation identified by molecular detection. The outbreaks should be confirmed by central testing prior to enrollment into the group.

In some embodiments, for NSCLC, the subject may receive a platinum-based combination therapy and/or targeted therapy (i.e., if molecular testing has identified a mutation in EGFR, ALK, or proto-oncogene tyrosine protein kinase ROS [ ROS1] or programmed death ligand [ PD-L1] expression) prior to receiving AMG 510 (compound a).

In some embodiments, the NSCLC in the subject must have progressed following receipt of anti-PD 1 or anti-PD-L1 immunotherapy (unless contraindicated) and/or platinum-based combination chemotherapy and targeted therapy if actionable oncogenic driver mutations [ i.e., EGFR, ALK, and ROS1] are identified. The subject must have received no more than 3 prior treatment lines.

In some embodiments of colorectal cancer (CRC), the subject must receive at least 2 prior systemic regimens in the event of metastasis. For those CRC subjects with MSI-H tumors, if they are clinically able to receive inhibitors and 1 of these agents is approved for the indication in the region or country, at least 1 of the previous systemic regimens must be treated with nivolumab or palbociclumab.

In some embodiments, CRC of a subject must progress after receiving fluoropyrimidine and oxaliplatin and irinotecan. For those CRC subjects with MSI-H tumors, if they are clinically able to receive inhibitors and 1 of these agents is approved for the indication in the region or country, at least 1 of the previous systemic regimens must include anti-PD 1 therapy.

In some embodiments, for advanced solid tumor types other than NSCLC or CRC, the subject must have received at least one previous systemic therapy that is intolerant or not in compliance with available therapies known to provide clinical benefit.

In some embodiments, a dose of compound a can optionally be administered to a subject with food (e.g., eating a standardized high fat, high calorie diet) or in a fasting state (no food or liquid (other than water) ≧ 10 hours). In one embodiment, a dose of compound a (e.g., 960mg once daily) is administered with or without food.

Adverse Events (AEs) were monitored during therapy in subjects receiving therapy. A treatment-related AE is a therapeutic drug-related AE. An AE that occurs during the treatment period is one that is not present in the subject prior to the initiation of therapy and occurs during the course of treatment. In some cases, the AE that occurred during the treatment period was not related or suspected to be unrelated to the treatment itself. AE is characterized by one of five levels: grade 1 is mild AE; grade 2 is moderate AE; grade 3 is severe AE; grade 4 AE life threatening or disabling; AE-related deaths were rated 5. In some cases, the subject did not exhibit any treatment-related grade 3 AEs. In some cases, the subject did not exhibit any grade 3 AE. In some cases, the subject did not exhibit any treatment-related grade 4 AEs. In some cases, the subject did not exhibit any grade 4 AE. In each case, the subject did not exhibit treatment-related grade 3 or 4 AEs at least one month or at least three months after administration of compound a.

In various instances, the subject treated with compound a in the methods disclosed herein does not exhibit any dose-limiting toxicity (DLT) at the dose administered. DLT is any AE occurring in the first treatment cycle (day 1 to day 21) of compound a that meets the criteria listed below, wherein drug-related relationships cannot be excluded. The grading of AE is based on the guidelines provided in CTCAE version 5.0. AE for DLT evaluation:

hematological toxicity: a decrease in febrile neutrophils; neutropenic infection; grade 4 neutropenia; grade 3 or more thrombocytopenia >7 days; grade 3 thrombocytopenia with grade 2 bleeding or more; grade 4 thrombocytopenia; grade 4 anemia

Non-hematologic toxicity is not less than grade 4, vomiting or diarrhea; grade 3 diarrhea or grade 3 vomiting persists for more than 3 days despite optimal medical support; grade 3 nausea lasted 3 or more days, despite optimal medical support; any other grade 3 AE

In each case, the subject of the disclosed methods exhibits a response to the therapy. In certain instances, the subject exhibits at least a Stability Disorder (SD) as a result of administration of compound a. In certain instances, the subject exhibits at least a Partial Response (PR) as a result of administration of compound a. The subject's response is assessed by criteria defined by RECIST 1.1 (e.g., as discussed in Eisenhauer et al, EurJcancer [ Eur. J. cancer ], 45: 228-. Complete Response (CR) is the disappearance of all target lesions and the reduction of the minor axis of any pathological lymph node to less than 10 mm. Partial Response (PR) is a reduction of at least 30% in the sum of target lesion diameters, relative to the sum of baseline diameters. Progressive disease means that the sum of target lesion diameters is increased by at least 20% with reference to the minimum sum in the study (including the baseline sum if the baseline sum is the minimum sum in the study), and must have an absolute increase of at least 5mm in addition to a relative increase of 20%. Stable disease is neither sufficiently reduced to comply with PR, nor sufficiently increased to comply with PD. A controlled disease state is a condition in which a patient may alternate between exhibiting stable disease and partial response. Tumor size can be measured by radiographic scanning.

Combination therapy

The present disclosure also provides methods for combination therapy wherein agents known to modulate other pathways, or other components of the same pathway, or even overlapping sets of target enzymes, are used in combination with compound a or a pharmaceutically acceptable salt thereof. In one aspect, such therapies include, but are not limited to, the combination of compound a and chemotherapeutic agents disclosed herein to provide a synergistic or additive therapeutic effect.

A number of chemotherapeutic agents are currently known in the art and may be used in combination with compound a. In some embodiments, the chemotherapeutic agent is selected from the group consisting of: mitotic inhibitors, alkylating agents, antimetabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, anti-hormonal agents, angiogenesis inhibitors, and anti-androgens. Non-limiting examples are chemotherapeutic agents, cytotoxic agents and non-peptide small molecules, e.g.(imatinib mesylate),(carfilzomib) and (iii) and (iv) a salt thereof,(bortezomib), Casodex (bicalutamide),(Gefitinib), Venclexta^TM(Veratrix) and Adriamycin^TM(doxorubicin), and various chemotherapeutic agents. Non-limiting examples of chemotherapeutic agents include alkylating agents, such as thiotepa and cyclophosphamide (Cytoxan)^TM) (ii) a Alkyl sulfonates such as busulfan, improsulfan, and piposulfan; aziridines such as benzotepa, carboquone, meturedpa and uredpa; ethyleneimine and methylmelamine including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, and trimethylolmelamine; nitrogen mustards, such as chlorambucil, cyclophosphamide chloride, estramustine, ifosfamide, dichloromethyldiethylamine, mechlorethamine hydrochloride (mechlorethamine oxide hydrochloride), melphalan, neonebivhin (novembichin), benzene mustarne cholesterol (phenesterine), prednimustine, trofosfamide, uracil mustard; nitrosoureas such as carmustine, chlorourethrin, fotemustine, lomustine, nimustine, ramustine; antibiotics, such as aclacinomycin (acrinomycin), actinomycin (actinomycin), antromycin (aurramycin), azaserine, bleomycin, actinomycin C (cactinomycin), calicheamicin (calicheamicin), carubicin (carabicin), carminomycin, carzinophilin (carzinophilin), Casodex^TMTryptophamycin, dactinomycin, daunomycin, ditetracycline, 6-diazo-5-oxo-L-norleucine, doxorubicin, epirubicin, esorubicin, idarubicin, marijumycin (marcelomycin), mitomycin, mycophenolic acid, nogomycin, olivomycin, pelomycin, pofiomycin (potfiromycin), puromycin, triiron doxorubicin (quelemycin), rodabicin, streptonigrin, streptozotocin, tubercidin, ubenimex, setastin, zorubicin; antimetabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogues, e.g. denopterin, methotrexate, pteropterin, trimaranTriple bolus of daqu sand; purine analogs such as fludarabine, 6-mercaptopurine, thiamine, thioguanine; pyrimidine analogues such as, for example, azacitidine (azacitidine), azacitidine, 6-azauridine, carmofur (carmofur), cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, androgens such as carpoterone, drostanolone propionate, epithioandrostanol, meptazinane, testolactone; anti-adrenal agents, such as aminoglutethimide, mitotane, trostane; folic acid supplements, such as folinic acid (frilic acid); acetoglucurolactone (acegultone); (ii) an aldophosphamide glycoside; aminolevulinic acid (aminolevulinic acid;); amsacrine (amsacrine); doubly-branched betuzucil; bisantrene; edatrexate (edatraxate); desphosphamide (defofamine); colchicine (demecolcine); diazaquinone (diaziqutone); efluoromithine (elfosmithine); ammonium etitanium acetate; etoglut (etoglucid); gallium nitrate (gallium nitrate); hydroxyurea (hydroxyurea); lentinan (lentinan); lonidamine (lonidamine); mitoguazone (mitoguzone); mitoxantrone (mitoxantrone); mopidamol (mopidamol); nitraminoacrridine (nitracrine); pentostatin (pentostatin); methionine mustard (phenamett); pirarubicin (pirarubicin); podophyllinic acid (podophyllic acid); 2-ethyl hydrazide (2-ethyl hydrazide); procarbazine (procarbazine); PSK; propyleneimine (razoxane); sizofuran (sizofiran); germanium spiroamines (spirogyranium); tenuazonic acid (tenuazonic acid); triimine quinone (triaziquone); 2,2' -trichlorotriethylamine; urethane (urethan); vindesine (vindesine); dacarbazine (dacarbazine); mannomustine (mannomustine); dibromomannitol (mitobronitol); dibromodulcitol (mitolactol); pipobromane (pipobroman); gasetsin (gacytosine); arabinoside ("Ara-C"); cyclophosphamide; thiotepa; taxanes (taxanes), such as paclitaxel (paclitaxel) and docetaxel (docetaxel); retinoic acid (retinic acid); epothilones (esperamicins); capecitabine (capecitabine); and pharmaceutically acceptable salts, acids or derivatives of any of the foregoing.

As is suitable forThe chemotherapeutic cell conditioning agents of (a) further include anti-hormonal agents, such as anti-estrogenic agents, including, for example, tamoxifen (Nolvadex) for modulating or inhibiting the effects of hormones on tumors^TM) Raloxifene, aromatase inhibiting 4(5) -imidazole, 4-hydroxyttamoxifen, trovaxifen, keoxifene (keoxifene), LY 117018, onapristone, and toremifene (fareton); and antiandrogens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; chlorambucil (chlorambucil); gemcitabine (gemcitabine); 6-thioguanine; mercaptopurine; methotrexate; platinum analogs, such as cisplatin and carboplatin; vinblastine (vinblastine); platinum; etoposide (VP-16); ifosfamide; mitomycin C; mitoxantrone (mitoxantrone); vincristine (vincristine); vinorelbine (vinorelbine); navelbine (navelbine); nuantro (novantrone); teniposide (teniposide); daunomycin (daunomycin); aminopterin; (xiloda); ibandronate (ibandronate); camptothecin-11 (CPT-11); topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO).

Compound A can be used in combination with conventionally prescribed anticancer drugs, such as ABVD, Avicine (AVICINE), Abamezumab (Abagolomab), Acridine carboxamide (Acridine carboxamide), Adlemab (Adecatumumab), 17-N-allylamino-17-demethoxygeldanamycin, Alpharadin (Alpharadin), Avoxicib (Alvocidib), 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, Amonafide (Amonatide), Anthracenedione (Anthracenedione), anti-CD 22 immunotoxins, anti-neoplastic agents, anti-tumorigenic herbs (Antitumorigenic herbs), Apatiquone (Apazoquuone), Atiprimod (Atiprimod), Azathioprine (Azathroprione), Belotecan (Belotecan), Bendamustine (Bendamustine), BW 2992, bicardida (B2992)iricrodar, betalain (Brostallicin), Bryostatin (Bryostatin), Buthionine sulfoximine (Buthionine sulfoximine), CBV (chemotherapy), Calyculin (Calycolin), cell cycle non-specific antineoplastic agents, dichloroacetic acid, Discodermolide (Discodermolide), Elsamitrucin (Elsamirutrucin), Enocitabine (Enocitabine), Epothilone (Epothilone), Eribulin (Eribulin), Everolimus (Everolimus), irinotecan (Exatecan), exemestane (Exisulinnd), Ferruginol (Ferruginol), flonicamid (Forodesine), fosstrol (Fosfstrol), chemotherapeutic regimens, IT-101, Immexeon (Exexen), Imiquimod (Imidocarbazole), luteolin (Irazone), Ludoxamide (Luofuramide), Luofuracil (Luofuracil), Luofuracil (Luffamine), Luffamine (L), Luffamine (Iressone (L), Luffamine (L), Luffamine (L-L (L-L (L) and L-L (L-L (L-L) can, L-L (L-L ) can, L-L (L-L, Nafoxidine (Nafoxidine), Nedaplatin (Nedaplatin), Olaparib (Olaparib), Ortataxel (Ortataxel), PAC-1, Pawpaw, Pixantrone (Pixantrone), proteasome inhibitors, bleomycin (Rebeccamycin), Resiquimod (Resiquimod), Rubitecan (Rubitecan), SN-38, salinosporamide a (salinosporamide a), sapapatabine (Sapacitabine), stanford v (stanford v), Swainsonine (Swainsonine), Talaporfin (Talaporfin), taloquina (Tariquidar), eufudine (teguacil), Temodar (Temodar), Tesetaxel (Tesetaxel), Triplatin tetranitrate (Triplatin), Triplatin trinity 612 (triptolide), trovafluzine (vafluquine), vinfluquine (vilazone), trovafluquine (vil), or vinfluquinacrine (vil).

Compound A is contemplated for use in co-therapy with a chemotherapeutic agent that is an antineoplastic agent, e.g., acemannan (acemannan), aclarubicin, aldesleukin, alemtuzumab (alemtuzumab), alitretinoin (alitretinin), altretamine, amifostine, aminolevulinic acid, amrubicin, amsacrine, anagrelide, anastrozole, ANCER, acestim (ancestam), argalabi (ARGLABIN), arsenic trioxide, BAM 002 (Novel) andos)), bexarotene (bexarotene), bicalutamide, bromouridine, capecitabine, simethiol, cetrorelix, cladribine, clotrimazole, cytarabine octadecylphosphate (cytarabine ocfosfate), DA 3030(Dong-a), daclizumab (daclizumab), dinil interleukin (denileukin difitox), deslorelin (deslorelin), dexrazoxane, dilazep (dilazep), doxycycline, behenyl alcohol (doxercifonol), doxifluridine, doxorubin, bromocriptine, carmustine, cytarabine, fluorouracil, HIT diclofenac, interferon- α, daunomycin, doxorubicin, retinoic acid, edelfosine, edereuteriol, efolithine (eloritinine), ethitifloxifene, epirubicin, beta-sitagliptin, etoposide, meglitinide, egelminth (etaxorubicin), etisofalctin (efavirenz-a), docetaxel, doxiflavine (doxiflavine), ethisterone, epirubicin, etalin, etamsin (etisulindafurtin), favudine, doxiflavine, mise, doxiflavine, mise, doxiflavine, dox, Finasteride, fludarabine phosphate, formestane (formestane), fotemustine, gallium nitrate, gemcitabine, gemtuzumab ozogamicin (gemtuzumab zogamicin), gimeracil/oteracil/tegafur combination, glatiramerine (glycopine), goserelin, heptaplatin (heptraplatin), human chorionic gonadotropin, human fetal alpha fetoprotein, ibandronic acid, idarubicin, imiquimod, interferon-alpha, natural interferon-alpha-2, interferon-alpha-2 a, interferon-alpha-2 b, interferon-alpha-N1, interferon-alpha-_n3Interferon alfacon-1, interferon alpha, natural interferon beta, interferon beta-1 a, interferon beta-1 b, interferon gamma, natural interferon gamma-1 a, interferon gamma-1 b, interleukin-1 beta, iodobenzylguanidine, irinotecan, issorodin (irsogladine), lanreotide (lanreotide), LC 9018 (Yanglaux group (Yakult)), leflunomide, lenograstine (lenograstim), lentinan sulfate, letrozole, leukocyte alpha interferon, leuprorelin, levamisole + fluorouracil, liazole (liarozole), lobaplatin, lonidamine, lovastatin, misoprostol, melarsinol, metoclopramide, mifepristone, miltefosine, mismatching mitoxantin, double stranded RNA, mitoxantrone, dibromodulcitol, mitoxantrone, monatin (molgrastim), zoledrinone + farnesone, and valsartan + farnesylne, Nartostim and neddaPlatinum, nilutamide (nilutamide), narcotine, novel erythropoiesis stimulating proteins, NSC 631570 octreotide, opperelin (opreflexekin), oxaprotamine, oxaliplatin (oxalapitin), paclitaxel, pamidronic acid, pemetrexed, peginterferon- α -2b, sodium xylopolythionate (pentanosolurate sodium), pentostatin, pisatin (pisibanil), pirarubicin, rabbit anti-thymocyte polyclonal antibody, peginterferon- α -2a, porfimer sodium, raloxifene, raltitrexed, lasermatorium (rasibunodime), rhenium hydroxide (Re 186), RII veovamide (RII retinamide), rituximab, romycin, lisocyst (samaria) (sarsastimaria (153), sargastixinafamim (153), sargassum (89), sargassum (sargassum), sargassum (89), strontium chloride (sargentamicin), sargentin (pamidronate), sargentamicin (89), sargentamicin (pavine), pemetronin (paviniferin), pemetrexed), pemphitin (p), pemphitin (alpha-2 b), pemphitin (alpha-2 a), pemphitin, naftifine, ralfate, raloxifenesin (r) and other compounds, Tasolomide (tasonermin), tazarotene, tegafur, temoporfin (temoporfin), temozolomide, teniposide, tetrachlorodecaoxide (tetrachlordecaoxide), thalidomide, thymalfasin, thyrotropin alpha, topotecan (topotecan), toremifene, tositumomab (tositumomab) -iodine 131, trastuzumab, troosulfan, tretinoin, tromestane, trimetrexate, triptorelin, tumor necrosis factor alpha (native), ubenimex, bladder cancer vaccine, Maruyama (Maruyama) vaccine, melanoma lysate vaccine, valrubicin (valrubicin), verteporfin, vinorelbine, vilrilulin (virulin), stastistin ester (zinostatimamer) or zoledronic acid; abarelix (abarelix); AE 941 (Aeterna), AMMOISTIN (ambamustine), antisense oligonucleotides, bcl-2 (Zhenta), APC 8015 (Dandereon), cetuximab, decitabine (decitabine), Dexaminoglutethimide (dexamiogluteside), diazaquinone, EL 532 (Elan), EM 800 (Endoliche), Enuracil, etanidazole, FenvA ammonium (fenretinide), Fegrastim SD01 (America), fulvestrant, Galotabine, gastrin 17 immunogen, HLA-B7 gene therapy (Vical), granulocyte macrophage colony stimulating factor, histamine dihydrochloride, ilomamab, Iltimumab, IM 862 (Cytran), interleukin-2, Epoxifene (iproxifene), LDI200 (Milkhaus), lerisitine (leriditim), lintuzumab (lintuzumab), CA 125Mab (Pamira), cancer Mab (Japanese pharmaceutical Development corporation), HER-2 and Fc Mab (Meddara), idiotypic 105AD7 Mab (CRC Technology), idiotypic CEAMAb (Trilex), LYM-1-iodine 131Mab (Techniclone), polymorphic epithelial mucin-yttrium 90MAb (Antersoma), Marisimastat (Metanosimae), Melimomab (sulfamimastat), Melanomorph, Millimolimumab (sulfamethab), gadolinium (gadolinium methorphan), gadolinium methorphan (gadolinium methorphan), gadolinium (gadolinium methorphan), and manganese (Biocide), and the like, P30 protein, pegvisomant (pegvisomant), pemetrexed, posomycin (porfiromycin), promastistat (prinomastat), RL 0903 (fire), lupitan, satraplatin (satraplatin), sodium phenylacetate, spapamoic acid (sparfosic acid), SRL 172(SR pharmaceutical), SU 5416 (Sugen)), TA 077 (Tanabe), tetrathiomolybdate, calophylline (thiamiblastine), thrombopoietin, purothromycin (tin ethyl ethylpurrin), tirapazamine, cancer vaccine (bamila), melanoma vaccine (new york university), melanoma vaccine (Sloan kenting Institute), melanoma lysate vaccine (new york medical College), viral melanoma cell lysate vaccine (Royal new york Hospital (Royal new castle)), or valsalva (valdecor).

Compound a may be used in combination with chemotherapeutic agents that are PD1 inhibitors, PDL1 inhibitors, MEK inhibitors, PI3K inhibitors or CDK4/6 inhibitors.

KRAS of the present disclosure^G12CThe inhibitors may be used in combination with MEK inhibitors. Specific MEK inhibitors that may be used in the combinations of the present disclosure include PD-325901, trametinib, pimecretin, MEK162[ also known as bimatinib]TAK-733, GDC-0973 and AZD 8330. May be combined with KRAS in the combinations of the present disclosure^G12CA particular MEK inhibitor used together is trametinib (trade name:available from Novartis Pharmaceuticals Corp.). Another specific MEK inhibitor is N- (((2R) -2, 3-dihydroxypropyl) oxy) -3, 4-difluoro-2- ((2-fluoro-4-iodophenyl) amino) benzamide, also known as AMG 1009089, 1009089 or PD-325901. Another specific MEK inhibitor that may be used in the combinations of the present disclosure includes cobicistinib (cobimetinib). In certain instances, the MEK inhibitor is CI-1040, AZD6244, PD318088, PD98059, PD334581, RDEA119, ARRY-142886, ARRY-438162, or PD-325901.

In another aspect, compound a may be used in combination with one or more agents that are inhibitors of proteins in the phosphatidylinositol 3-kinase (PI3K) pathway. Examples of proteins in the PI3K pathway include PI3K, mTOR, and PKB (also known as Akt or Akt). PI3K protein exists in several isoforms, including alpha, beta, delta, or gamma. It is expected that PI3K inhibitors may be selective for one or more isoforms. Selectivity refers to the compound inhibiting one or more isoforms more than other isoforms. Selectivity is a concept well known to those skilled in the art and can be measured using well known in vitro or cell-based activity assays. Preferred selectivities include selectivities to one or more isoforms that are greater than 2-fold, preferably 10-fold, or more preferably 100-fold, selective to other isoforms. In one aspect, the PI3K inhibitor that may be used in combination with compound a is a PI3K α selective inhibitor. In another aspect, the compound is a PI3K δ selective inhibitor. In yet another aspect, the compounds are selective inhibitors of PI3K β.

Examples of PI3K inhibitors that may be used in combination with compound a include those disclosed in: PCT published application numbers WO 2010/151791; PCT published application numbers WO 2010/151737; PCT published application numbers WO 2010/151735; PCT published application numbers WO 2010151740; PCT published application numbers WO 2008/118455; PCT published application numbers WO 2008/118454; PCT published application numbers WO 2008/118468; U.S. published application nos. US 20100331293; U.S. published application nos. US 20100331306; U.S. published application nos. US 20090023761; U.S. published application nos. US 20090030002; U.S. published application nos. US 20090137581; U.S. published application nos. US 2009/0054405; U.S. published application No. u.s.2009/0163489; U.S. published application nos. US 2010/0273764; U.S. published application No. u.s.2011/0092504; or PCT published application number WO 2010/108074.

In particular, PI3K inhibitors include, but are not limited to, wortmannin, the 17-hydroxywortmannin analog described in WO 06/044453, 4- [2- (1H-indazol-4-yl) -6- [ [4- (methylsulfonyl) piperazin-1-yl ] methyl ] thieno [3,2-d ] pyrimidin-4-yl ] morpholine (also known as GDC0941 and described in PCT publication nos. WO 09/036,082 and WO 09/055,730), 2-methyl-2- [4- [ 3-methyl-2-oxo-8- (quinolin-3-yl) -2, 3-dihydroimidazo [4,5-c ] quinolin-1-yl ] phenyl ] propionitrile (also known as BEZ235 or NVP-BEZ 235, and described in PCT publication No. WO 06/122806, (S) -1- (4- ((2- (2-aminopyrimidin-5-yl) -7-methyl-4-morpholinothieno [3,2-d ] pyrimidin-6-yl) methyl) piperazin-1-yl) -2-hydroxypropan-1-one (described in PCT publication No. WO 2008/070740), LY294002(2- (4-morpholino) -8-phenyl-4H-1-benzopyran-4-one, available from Achromon medical Chemicals (Axon), PI 103 hydrochloride (3- [4- (4-morpholino pyrido- [3',2': 4), 5] furo [3,2-d ] pyrimidin-2-yl ] phenolate hydrochloride available from Achroman medical chemical company), PIK 75(N' - [ (1E) - (6-bromoimidazo [1,2-a ] pyridin-3-yl) methylene ] -N, 2-dimethyl-5-nitrobenzenesulfonyl-hydrazide hydrochloride available from Achroman medical chemical company), PIK 90(N- (7, 8-dimethoxy-2, 3-dihydro-imidazo [1,2-c ] quinazolin-5-yl) -nicotinamide available from Achroman medical chemical company), GDC-0941 disulfonate (2- (1H-indazol-4-yl) -6- (4-methanesulfonyl-piperazin-1-ylmethyl-piperazin-5-yl) -nicotinamide) ) -4-morpholin-4-yl-thieno [3,2-d ] pyrimidine disulfonate, available from Achroman medical Chemicals), AS-252424(5- [1- [5- (4-fluoro-2-hydroxy-phenyl) -furan-2-yl ] -methyl- (Z) -ylidene ] -thiazolidine-2, 4-dione, available from Achroman medical Chemicals), and TGX-221 (7-methyl-2- (4-morpholinyl) -9- [1- (phenylamino) ethyl ] -4H-pyrido- [1,2-a ] pyrimidin-4-one, available from Achroman medical Chemicals)), XL-765 and XL-147. Other PI3K inhibitors include demethoxychlorovirin (demethoxyviridin), piperacillin, CAL101, PX-866, BEZ235, SF1126, INK1117, IPI-145, BKM120, XL147, XL765, Paromid 529(Palomid 529), GSK1059615, ZSTK474, PWT33597, IC87114, TG100-115, CAL263, PI-103, GNE-477, CUDC-907, and AEZS-136.

Preferred PI3K inhibitors for use in combination with the compounds of the present disclosure include:also known as buparnixine, a research small molecule from Novartis Pharmaceuticals (Novartis Pharmaceuticals); or a pharmaceutically acceptable salt thereof.

Also preferred as PI3K inhibitors are compounds of formula IIa or a pharmaceutically acceptable salt thereof,wherein X¹Is fluorine or hydrogen; y is¹Is hydrogen or methyl; and Z¹Is hydrogen or methyl. A particular PI3K inhibitor that may be used in the combination is AMG 511 (also known as AMG 2539965 or 2539965), which is example 148 of published PCT application WO 2010/126895.

Other PI3K inhibitors that may be used in combination with compound a in the combinations disclosed herein include Pan-PI3K inhibitors, such as BKM120 and GDC-0941; PI3K α selective inhibitors, such as AMG 511 and BYL 719; and PI3K β selective inhibitors, such as GSK-2636771.

Compounds that inhibit both PI3K and mTOR (dual inhibitors) are known. In yet another aspect, the present disclosure provides a dual inhibitor of PI3K and mTOR with KRAS^G12CThe use of a combination of inhibitors. An example of a specific dual inhibitor is GDC-0980.

mTOR is in the PI3K pathwayThe protein of (1). Another aspect of the disclosure is the use of an mTOR inhibitor with KRAS^G12CThe inhibitors are used in combination. mTOR inhibitors that may be used in combination with compound a include those disclosed in the following documents: PCT published application No. WO 2010/132598 and PCT published application No. WO 2010/096314. mTOR inhibitors that may be used in combination with compound a include AZD2014 and MLN 0128.

Pkb (akt) is also a protein in the PI3K pathway. Another aspect is the use of an AKT inhibitor in combination with compound a. AKT inhibitors that may be used include those disclosed in the following documents: U.S. patent nos. 7,354,944; U.S. patent nos. 7,700,636; U.S. patent nos. 7,919,514; U.S. patent nos. 7,514,566; U.S. patent application publication nos. US 2009/0270445 a 1; U.S. patent nos. 7,919,504; U.S. patent nos. 7,897,619; or PCT published application number WO 2010/083246 a 1. Specific AKT inhibitors that may be used in combination include MK-2206, GDC-0068 and AZD 5363.

Compound a may also be used in combination with CDK4 and/or CDK6 inhibitors. Inhibitors of CDK4 and/or CDK6 that may be used in the combinations of the invention include, but are not limited to, those disclosed in the following documents: PCT published application number WO 2009/085185 or U.S. patent application publication number US 2011/0097305.

anti-PD-1 antibodies include, but are not limited to, Pabolizumab (Keytruda)^TM) Nivolumab, AUNP-12, AMG401, and pidilizumab. Exemplary anti-PD-1 antibodies and methods of use thereof are described in the following documents: goldberg et al, Blood]110(1) 186-192 (2007); thompson et al, clin]13(6) 1757-1761 (2007); and Korman et al, international application No. PCT/JP2006/309606 (publication No. WO 2006/121168 a1), each of which is expressly incorporated herein by reference.

Compound a may be used in combination with the agents disclosed herein or other suitable agents, depending on the condition being treated. Thus, in some embodiments, compound a will be co-administered with other agents as described above. When used in combination therapy, compound a is administered simultaneously or separately with the second agent. Such combined administration may include simultaneous administration of two agents in the same dosage form, simultaneous administration of separate dosage forms, and separate administration. That is, compound a and any of the agents described above may be formulated together in the same dosage form and administered simultaneously. Alternatively, compound a and any of the agents described above can be administered simultaneously, with both agents present in separate formulations. In another alternative, any of the agents described above may be administered immediately after administration of compound a, or vice versa. In some embodiments of the separate administration regimen, the administration of compound a and any of the agents described above are separated by a few minutes, or by a few hours, or by a few days.

Examples

Phase 1 study of Compound A

A.First time result

Compound a dosing study: cancer patients identified as having the KRAS G12C mutation were enrolled in the cohort study. The patient is an adult patient with a locally advanced or metastatic KRAS G12C mutant solid tumor. All patients previously received prior standard therapy depending on tumor type and disease stage. No patient developed active brain metastases. Patients in the dosing study had the following diagnosis: 14 non-small cell lung carcinomas (NSCLC), 10 colorectal carcinomas (CRC), and two additional KRAS G12C mutant solid tumors. Compound a was administered orally once daily at the indicated dose. Patients were given a dose of 180mg, 360mg, 720mg or 960mg of compound a and radiographic scans were performed every six weeks.

Adverse events reported upon administration of compound a are shown in tables 1 and 2 below. Of the six serious adverse events reported, none was reported as related to compound a. Six serious adverse events were grade 3 two (pneumonia 1, malignant biliary obstruction 1); grade 4, 1 example (pericardial effusion); fatal 3 cases (1 dyspnea, 2 colorectal cancer metastases). No patient reported any DLT, grade 4 related adverse events, or severe related adverse events.

TABLE 1 adverse events occurring during the treatment period

TABLE 2 adverse events associated with treatment

Grade 3 adverse events	n
		Anemia (anemia)	1
Diarrhea (diarrhea)	1

^aPatients had grade 2 anemia at baseline;^blasting for 2 days

Individual response to compound a therapy: case 1: a 61 year old female diagnosed with KRAS G12C metastatic NSCLC in 2010 received the following prior therapy: carboplatin/Taxol from 8 months 2010 to 10 months 2010; then carboplatin/pemetrexed from 2016 for 10 months to 2017 for 6 months; then nivolumab between 8 months in 2017 and 4 months in 2018; compound a was then administered at a dose of 180 mg. In one of her six-week assessments, she showed a partial response at 180mg dose (-34%). She had tolerated the drug and continued to use it for over 27 weeks.

Case 2: a 59 year old male diagnosed with KRAS G12C metastatic NSCLC in 2013 received the following prior therapy: carboplatin/pemetrexed from month 2 in 2014 to month 2 in 2015; erlotinib 4-2015 to 2015 6-month; nivolumab 8 month-2017 month 2015; dasatinib from 7 months 2016 to 8 months 2017; m3541 (targeted biologies) from 10 months in 2017 to 11 months in 2017; compound a was then administered at a dose of 360 mg. He showed a partial response (-80%) in one of his six weeks of evaluations. He had tolerated the drug and continued to use it for more than 14 weeks.

Case 3: a 34 year old female diagnosed with KRAS G12C metastatic colon adenocarcinoma in 2014 received the following prior therapies: FOLFOX and HIPEC 8 months 2015, followed by FOLOX until 12 months 2015; FOLFIRI with PD at 8 months in 2016; HIPEC 10 months in 2016; capecitabine + bevacizumab for 8 months in 2017; clinical trial at stage I, 3-6 months in 2018; compound a was then enrolled in a 2018, 10 month, phase I clinical trial of compound a and administered at a dose of 360 mg. In one of her six-week assessments, she showed stable disease (-18%). She also exhibited a biochemical response in which her biomarkers CA19-9 and CAE dropped rapidly after compound a administration and remained at lower levels during compound a therapy (fig. 1). She had tolerated the drug and continued treatment for over 22 weeks.

NSCLC tumor response: KRAS G12C NSCLC patients were given daily doses of 180mg, 360mg, 720mg or 960mg and 9 of 10 patients in the study showed at least a stable disease response to therapy according to radiographic scans taken every six weeks-the results are shown in figure 2, with the indicated dose indicated below each histogram. The duration and treatment of subjects in the NSCLC study is also shown in fig. 3, where the top four columns are patients receiving a total daily dose of 960mg, and the next six columns are patients receiving a total daily dose of 720 mg; the next column is the patient receiving a total daily dose of 360mg, and the bottom three columns are the patients receiving a total daily dose of 180 mg.

CRC and other solid tumor responses: KRAS G12C CRC patients or other solid tumor patients were given daily doses of 180mg, 360mg, 720mg or 960mg, and the results for 17 of the 19 patients studied are shown in figure 4 (two patients not shown progressed by week 6 and did not receive the first six week assessment). The results in fig. 4 are based on radiographic scans performed every six weeks of evaluation. The duration and treatment of subjects in the CRC/other study is also shown in figure 5, where the top two bars are patients receiving a total daily dose of 960mg, and the next five bars are patients receiving a total daily dose of 720 mg; the next seven columns are patients receiving a total daily dose of 360mg, and the bottom three columns are patients receiving a total daily dose of 180 mg.

Results of phase a1 study: thirty-five KRAS G12C cancer patients (19 CRCs, 14 NSCLCs, 2 other-appendiceal cancers) were enrolled in the phase 1 study of group compound a. All patients had 2 or more prior lines of therapy. No DLT was reported. Sixteen patients reported adverse events associated with compound a, two of which had grade 3 associated adverse events (anemia and diarrhea). The best tumor response was listed and 26 patients were still under study. The results are shown in table 3 below.

TABLE 3 adverse events associated with treatment

The pharmacokinetics of compound a at the oral administration dose of 960mg are as follows: c_{Maximum of}7.84. mu.g mL (SD 8.09); AUC_{0 to 24 hours}140hr μ g/mL (SD 117); and t_1/2,z6.5 hours (SD 4.2-8.0).

B.Updated results

More recent results from this Study have been obtained by Govindan, R. et al, "Phase 1 Study of AMG 510, a Novel KRAS^G12CG12CMUTation, [ AMG 510, a novel KRAS^G12CInhibitors, phase 1 study in advanced solid tumors with KRAS p.g12c mutation]"displayed as a poster at the european medical oncology society of oncology (ESMO) conference held at baselona, spain, on 2019, months 27-10, month 1, the contents of which are incorporated herein in their entirety. Additional results of this study are shown by: fakih, m.g., et al, "CodeBreak 100: activity of AMG 510, a novel small mobile inhibitor of KRAS^G12C，in patients with advanced colorectal cancer, [ codebeark 100: novel KRAS^G12CActivity of small molecule inhibitor AMG 510 in patients with advanced colorectal cancer]And Hong, d.s., et al, "CodeBreak 100: phase 1 study of AMG 510, alpha novel KRAS^G12Cinhibitor, in documents with advanced soluble tumors other than non-small-cell lung cancer (NSCLC) and colour cancer (CRC) [ CodeBreak 100: novel KRAS^G12CPhase 1 study of inhibitor AMG 510 in patients with advanced solid tumors other than non-small cell lung cancer (NSCLC) and colorectal cancer (CRC)]"on the American Society for Clinical Oncology (ASCO) conference, 5 months 29 to 31 days 2020 (in fact), the contents of which are incorporated herein in their entirety.

The Study is also published as "A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of AMG 510 in subjects with a Specific KRAS Mutation (CodeBreak100)," clinical trial government identification number NCT 03883, https:// clinical trials. gov/ct 52/show/NCT 03600883 (final visit time: 2020, 5 months and 3 days), the contents of which are incorporated herein in their entirety.

The following data indicate that compound a shows promising early anti-tumor activity in patients with advanced solid tumors (such as NSCLC, CRC and other tumor types) with the krasp. g12c mutation.

Clinical trial design is briefly described in the protocol below.

^aSafety follow-up was performed 30(+7) days after the end of treatment; long-term follow-up was performed every 12 weeks. PK: pharmacokinetics: PFS: survival without progression.

I.Non-small cell lung cancer (NSCLC) patients

The first patient was enrolled in the group on day 8, month 27, 2018. By 17 days 7 and 7 of the expiration date 2019, 76 patients were enrolled, 34 of which had NSCLC (1 had SCLC (this patient was recorded as SCLC ("other tumor type" category) at the time of data expiration, was changed to NSCLC by the participating site after expiration). 45 patients were enrolled in an ascending cohort (180mg total daily dose (N ═ 6), 360mg total daily dose (N ═ 13), 720mg total daily dose (N ═ 11), 960mg total daily dose (N ═ 15)) and 31 patients were enrolled in an expanding cohort (960mg total daily dose (N ═ 31)), resulting in 55 evaluable patients who had the first 6-week scan (first 6-weescan) or had early Progressive Disease (PD). among the 76 patients enrolled in the cohort, 52 continued to receive treatment and 24 were worth the treatment due to PD (N ═ 22) and death (N ═ 2), none of the discontinuations were due to treatment-related adverse reactions.

TABLE 4 Baseline characteristics

^aThe tumor type of this patient was recorded as SCLC (other tumor types) by data cutoff; after expiration, the participating sites updated the tumor type to NSCLC. CRC for colorectal cancer; ECOG — eastern american tumor cohort; NSCLC ═ non-small cell lung cancer; SCLC ═ small cell lung cancer.

The following table summarizes the incidence of Adverse Events (AEs) in patients. No dose limiting toxicity was reported. In addition, no serious or fatal AE associated with treatment were reported. Most importantly, no treatment-related AE resulted in discontinuation of treatment. As a result, a total daily dose of 960mg of compound a was determined as the extension dose and the recommended phase 2 dose.

TABLE 5 summary of incidence of Adverse Events (AE) in patients

^aSeven namesThe patient had the following fatal AEs: dyspnea, aspiration, lung cancer metastasis, colorectal cancer metastasis, and spinal compression fracture; none are relevant to treatment.

^bTwo CRC patients discontinued treatment due to AE in metastatic colorectal cancer.

^cOne NSCLC patient had a respiratory infection, initially reported in snapshots as a treatment-related severe AE; after snapshot, the study site confirmed that this was not due to treatment, but rather to an underlying disease.

CRC for colorectal cancer; NSCLC ═ non-small cell lung cancer.

The following table details the incidence of treatment-related Adverse Events (AEs) for the patients. In summary, 26 of 76 patients (34.2%) reported treatment-related AEs, most of which were grade 1 or 2.6 of 76 patients (7.9%) reported 1 or more than 1 treatment-related grade 3 adverse events (diarrhea and anemia). There were no treatment-related adverse events at or above grade 4.

TABLE 6 incidence of treatment-related Adverse Events (AE) in patients

ALT ═ alanine aminotransferase; AST ═ aspartate aminotransferase.

The Pharmacokinetic (PK) profile of compound a (960mg total daily oral dose) up to a PK expiration date of 2019, 24 days 7 and 24 (N ═ 32, including NSCLC and CRC patients) was as follows (geometric mean;% Coefficient of Variation (CV)): maximum serum concentration (C)_{Maximum of})7.50 μ g/mL (98.3%), area under the curve (AUC)65.3hr μ g/mL (81.7%), elimination half-life (t)_1/2,z)5.5 hours (1.8). Serum concentrations remained higher than 90% inhibitory concentration in vitro for at least 22 hours after administration in a 2 hour cellular phosphorylation extracellular signal-regulated kinase (pERK) assayDegree (IC)₉₀)。

The following table reports the optimal tumor response for NSCLC patients at all dose levels and 960mg doses.

TABLE 7 incidence of treatment-related Adverse Events (AE) in patients

Efficacy results	Evaluable patient (N23)	Receiving 960mg of evaluable patient (N ═ 13)
			Optimal overall response
PR-n(％)	11(48)	7(54)
			SD-n(％)	11(48)	6(46)
PD-n(％)	1(4)	0(0)
			Objective response ratea	48％	54％
Rate of disease controlb	96％	100％

^aThe evaluation of the response is based on the modified RECIST 1.1 criterion.

^bPR or SD at week 6.

PR: partial response; SD: stability disorders; PD: progressive disease. Evaluable patients: patients with the first 6 week scan or with early PD.

The efficacy of compound a in NSCLC patients is shown in figure 6 (% change in the sum of the longest diameters compared to baseline compared to evaluable NSCLC patients with available post-baseline tumor data (N ═ 22.) it is noted that the rightmost bar represents patients treated with a total daily dose of 960mg who had a complete response to the target lesion.

Figure 7 shows the efficacy of compound a in NSCLC patients, observing the time of appearance of response and duration of treatment (evaluable NSCLC patients (N ═ 23) compared to duration of treatment (weeks)). 11 patients showed Partial Response (PR) with median duration of 15.1 treatment weeks (range 4.1-42.3). Of these 11 patients 8 are continuing the study. In addition, 11 patients exhibited Stable Disease (SD), with a median duration of 10.0 treatment weeks (range 4.1-35.1). Of these 11 patients 8 are continuing the study.

In summary, compound a showed promising early anti-tumor activity in patients with advanced solid tumors (e.g. NSCLC) with KRAS p.g12c mutation. Furthermore, compound a was found to have a good safety profile at the dose levels tested-no dose limiting toxicity was observed and no cumulative toxicity was noted with prolonged treatment.

II.Colorectal cancer (CRC) patient

42 CRC patients (cohort 1: 3 patients, 180mg total daily dose; cohort 2: 10 patients, 360mg total daily dose; cohort 3: 4 patients, 720mg total daily dose; cohort 4: 25 patients, 960mg total daily dose) were enrolled by the expiration date of 2020, 1 month, 8 days. The median follow-up period was 7.9 months (range: 4.2-15.9 months). 8 patients were continuing treatment. There were 34 patient aborts due to disease progression (32) and patient requirements (2). All enrolled patients received prior line systemic anti-cancer therapy. 45% of patients received more than 3 lines of treatment.

TABLE 8 Baseline characteristics

ECOG (eastern american) tumor cooperative group

The following two tables summarize the incidence of Adverse Events (AEs) in patients. Treatment-related adverse events were reported in 20 of 42 patients, most of which were grade 2 or lower. Diarrhea and anemia were reported as treatment-related grade 3 AEs, each occurring in 1 patient. There was no dose limiting toxicity. As described above, the total daily dose of 960mg of compound a was determined as the extension dose and the recommended phase 2 dose.

TABLE 9 summary of incidence of Adverse Events (AE) in patients

AE: adverse events

Table 10-treatment-related TEAE at any grade occurring in >1 patients

The following table reports the tumor response of CRC patients at all dose levels and a total daily dose of 960 mg. As for efficacy, confirmed partial responses were observed in 3 patients, all receiving a dose of 960 mg. The response is persistent and still responding by the date of the data expiration. In addition, 29 patients had stable disease, resulting in a disease control rate of 76.2%.

TABLE 11 tumor response

^aPatients had clinical progression and no post-baseline measurements.

+: and (4) cutting off the tail value.

Progression Free Survival (PFS) is shown in figure 8. Progression-free survival at all dose levels was 4.0 months (median (min, max), 0.7, 11.0), 4.2 months in the case of 960mg (median (min, max), 1.2, 5.7 +; +: cutoff). The PFS rates were 58.5% and 20.6% at 3 months and 6 months, respectively, for all doses. The PFS rate at 3 months for a total daily dose of 960mg was 59.7%. The Overall Survival (OS) is shown in fig. 9. The overall survival at all dose levels was 10.1 months (median (min, max), 1.3+, 11.4 +; +: cutoff; NR: not reached), NE (2.3, 8.0+) at 960 mg. The 6-month OS rate was 76.4% for all doses, and 82.9% for a total daily dose of 960 mg.

The efficacy of compound a in CRC patients is shown in figure 10 (% change in longest diameter sum compared to baseline compared to evaluable CRC patients with available post-baseline tumor data (N39) — 3 patients were not included in the graph of figure 10 due to lack of post-baseline tumor data (1 PD, 1 SD, 1 due to incomplete clinical progression).

FIGS. 11-15 show the tumor burden in CRC patients as a function of time from baseline at all four doses of Compound A (FIG. 11; total daily doses of 180mg, 360mg, 720mg, and 960mg) and for each individual dose (FIGS. 12-15).

Figures 16 and 17 show the time of appearance of response and treatment over time for CRC patients administered with various doses of compound a.

In summary, three of 42 patients with deeply pretreated krasp.g12c mutant metastatic CRC (7.1%) had a persistent partial response to compound a. In addition to 3 responders, 29 patients also achieved disease control, resulting in a disease control rate of 76.2% and median Progression Free Survival (PFS) of 4.0 months (range: 0.7-11.0). In addition, compound a was well tolerated in CRC patients with mild, treatment-related toxicity, consistent with previous results.

III.Patients with advanced solid tumors other than NSCLC and CRC

By the cutoff date of 2020, 1 month, 8 days, 25 patients with the following tumor types were enrolled: pancreatic cancer (10 patients), appendiceal cancer (4 patients), endometrial cancer (2 patients), cancer with an unknown primary focus (2 patients), cholangiocarcinoma (1 patient), sinus cancer (1 patient), ampulla cancer (1 patient), small intestine cancer (1 patient), melanoma (1 patient), small cell lung cancer (1 patient), and esophageal cancer (1 patient). 2 patients with appendiceal cancer received a total daily dose of 360mg and 720mg of Compound A, respectively. The remaining 23 patients received a total daily dose of 960mg of compound a. The median follow-up was 4.3 months (range: 0.1-12.6 months). 22 patients had been followed for 7 weeks or more and responses could be assessed. By the expiration date, 12 patients discontinued treatment, with disease progression being the most common cause. All patients enrolled in the group received prior line of systemic anti-cancer therapy, and 84% of the enrolled patients received more than 1 prior line therapy.

TABLE 12 Baseline characteristics

ECOG (eastern american) tumor cooperative group

The following table summarizes the incidence of Adverse Events (AEs) in patients. More than one patient reported treatment-related TEAEs as diarrhea (2 in 25 patients) and fatigue (2 in 25 patients). Reported treatment-related AEs at level 3 were diarrhea (1 in 25 patients) and pneumonia (1 in 25 patients). There was no dose-limiting toxicity and no treatment-related adverse events leading to discontinuation. As described above, the total daily dose of 960mg of compound a was determined as the extension dose and the recommended phase 2 dose.

TABLE 13 summary of patient Adverse Event (AE) incidence

AE: adverse events

The tumor response of these patients is reported in the table below. Tumor response was evaluated in 22 patients. 3 had confirmed partial responses, 13 had stable disease, and 6 had disease progression. 3 partial responders had appendiceal, melanoma and endometrial cancer, respectively. The 13 patients with stable disease include 6 pancreatic cancer, 2 appendiceal cancer, 1 ampulla cancer, 1 cholangiocarcinoma, 1 endometrial cancer, 1 sinus cancer, and 1 cancer with unknown primary focus. 3 pancreatic cancer patients with stable disease had a nearly 30% reduction according to RECIST 1.1.

TABLE 14 tumor response

The efficacy of compound a in these patients is shown in figure 18 (% change in sum of longest diameters compared to baseline compared to evaluable patients with available post-baseline tumor data (N ═ 19).; three patients were not included in the graph of figure 18 due to lack of post-baseline tumor data (2 patients with appendiceal cancer (1 PD, 1 SD) and one patient with pancreatic cancer (PD)).

Figure 19 shows the time of appearance of responses and treatment over time for these patients.

In summary, encouraging anti-cancer activity has been observed in a number of tumor types with KRAS G12C. Confirmed partial responses were observed in 3 patients with appendiceal, melanoma, and endometrial cancer, respectively. 6 of 8 evaluable pancreatic cancer patients demonstrated stable disease-three of them had a 30% reduction in tumor burden. The toxicity associated with compound a was mild and controlled, consistent with previous results.

While the invention has been described and illustrated with reference to certain particular embodiments thereof, those skilled in the art will appreciate that various adaptations, changes, modifications, substitutions, deletions, or additions of procedures and protocols may be made without departing from the spirit and scope of the invention. It is intended, therefore, that the invention be defined by the scope of the appended claims, and that such claims be interpreted as broadly as is reasonable.